Oxford Biomedica Announces Development Milestone in its Collaboration with Molmed
News Jan 23, 2008
Under a license agreement with Oxford BioMedica, MolMed’s TK therapy product employs Oxford BioMedica’s retroviral ex vivo gene delivery technology. The start of a Phase III trial of TK therapy triggers an undisclosed milestone payment to Oxford BioMedica.
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019